Although JAK2 mutations are commonly associated with adult hematological cancers like myeloproliferative neoplasms, there is growing evidence that JAK2 also plays a role in pediatric leukemia, including ALL and AML[3,4]. Here, JAK2 is linked to myeloproliferative disorder.